IP Library Granted Patent US 10,716,814
Granted Patent B2
US 10,716,814 · App. 16/206,235 · Granted Jul 21, 2020

Mesenchymal stem cells and uses therefor

Inventors: Sudeepta Aggarwal (North Potomac, MD); Mark F. Pittenger (Severna Park, MD); Timothy Varney (Baltimore, MD)
Assignee: Mesoblast International Sàrl
A61K35/28A61K38/2026A61K38/2066A61K45/06C12N5/0662C12N5/0663C12N5/0664C12N5/0665C12N5/0666C12N5/0667C12N5/0668A61K2035/124Y02A50/409
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,716,814
App. No.
16/206,235
Granted
Jul 21, 2020
Kind
B2
Abstract

Compositions and methods of promoting wound healing in a human by administering to the human mesenchymal stem cells in an effective amount.

Claims (22)

1. A method of reducing inflammation in the gut, skin, or liver in a patient in need thereof comprising administering cultured mesenchymal stem cells to the patient in an amount effective to reduce the inflammation, wherein the mesenchymal stem cells are not genetically engineered with one or more polynucleotides encoding a therapeutic agent.

2. The method of claim 1 , wherein the mesenchymal stem cells are allogeneic.

3. The method of claim 1 , wherein the mesenchymal stem cells are autologous.

4. The method of claim 1 , wherein the mesenchymal stem cells are administered as a cell suspension in a pharmaceutically acceptable liquid medium for inj ecti on.

5. The method of claim 1 , wherein the mesenchymal stem cells are administered intravenously.

6. The method of claim 1 , wherein the mesenchymal stem cells are administered intraarterially.

7. The method of claim 1 , wherein the mesenchymal stem cells are administered in amount of about 1×10 5 cells/kg to about 5×10 7 cells per kg.

8. The method of claim 1 , wherein the mesenchymal stem cells are administered in amount of about 1×10 6 cells/kg to about 5×10 6 cells per kg.

9. The method of claim 1 , wherein the mesenchymal stem cells were isolated from marrow.

10. The method of claim 9 , wherein the marrow is iliac crest marrow.

11. The method of claim 1 , wherein the mesenchymal stem cells were isolated from blood, skin, cord blood, muscle, fat, bone, or perichondrium.

12. The method of claim 2 , wherein the mesenchymal stem cells are administered as a cell suspension in a pharmaceutically acceptable liquid medium for injection.

13. The method of claim 2 , wherein the mesenchymal stem cells are administered intravenously.

14. The method of claim 2 , wherein the mesenchymal stem cells are administered intraarterially.

15. The method of claim 2 , wherein the mesenchymal stem cells are administered in amount of about 1×10 5 cells/kg to about 5×10 7 cells per kg.

16. The method of claim 2 , wherein the mesenchymal stem cells are administered in amount of about 1×10 6 cells/kg to about 5×10 6 cells per kg.

17. The method of claim 2 , wherein the mesenchymal stem cells were isolated from marrow.

18. The method of claim 17 , wherein the marrow is iliac crest marrow.

19. The method of claim 2 , wherein the mesenchymal stem cells were isolated from blood, skin, cord blood, muscle, fat, bone, or perichondrium.

20. The method of claim 1 , wherein inflammation in the gut is reduced.

21. The method of claim 1 , wherein inflammation in the skin is reduced.

22. The method of claim 1 , wherein inflammation in the liver is reduced.

Assignments (4)
RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jan 2, 2026
From: OAKTREE FUND ADMINISTRATION, LLC, AS AGENT
To: MESOBLAST LIMITED; MESOBLAST UK LIMITED; MESOBLAST, INC. (FORMERLY KNOWN AS ANGIOBLAST, INC.); MESOBLAST INTERNATIONAL SÀRL
Reel/Frame 074174/0183 →
SECURITY INTEREST Recorded Dec 10, 2021
From: MESOBLAST LIMITED ACN 109 431 870; MESOBLAST UK LIMITED; MESOBLAST, INC. (FORMERLY KNOWN AS ANGIOBLAST, INC.); MESOBLAST INTERNATIONAL SÀRL
To: OAKTREE FUND ADMINISTRATION, LLC
Reel/Frame 058957/0447 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 14, 2020
From: AGGARWAL, SUDEEPTA; PITTENGER, MARK F.; VARNEY, TIMOTHY
To: OSIRIS THERAPEUTICS, INC.
Reel/Frame 051824/0376 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 14, 2020
From: OSIRIS THERAPEUTICS, INC.
To: MESOBLAST INTERNATIONAL SARL
Reel/Frame 051824/0913 →
Cited By (6)
US 12,209,255 US 12,410,405 US 12,465,621 US 12,473,547 US 12,697,355 US 12,702,683